NEW YORK – AstraZeneca and Merck's olaparib (Lynparza) received approval on Thursday from China's National Medical Products Administration for newly diagnosed advanced ovarian cancer patients whose tumors have somatic or germline BRCA1/2 mutations.
The drug is intended to be used as a first-line maintenance treatment,which aims to prolong remission and reduce the risk of disease progression in this subset of patients.